Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
Crossref DOI link: https://doi.org/10.1007/s40261-016-0487-7
Published Online: 2016-12-17
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Liu, Chieh-Yu
Chen, Hui-Chun
Funding for this research was provided by:
Pfizer (Taiwan) (DN-PC-100-015)
License valid from 2016-12-17